HRMY Stock Summary and Trading Ideas (Harmony Biosciences Holdings | NASDAQ:HRMY)

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.

Harmony Biosciences Holdings trades on the NASDAQ stock market under the symbol HRMY.

As of May 20, 2024, HRMY stock price climbed to $29.72 with 358,621 million shares trading.

HRMY has a beta of 1.99, meaning it tends to be more sensitive to market movements. HRMY has a correlation of 0.15 to the broad based SPY ETF.

HRMY has a market cap of $1.69 billion. This is considered a Small Cap stock.

Last quarter Harmony Biosciences Holdings reported $155 million in Revenue and $.88 earnings per share. This fell short of revenue expectation by $-185,000 and exceeded earnings estimates by $.26.

In the last 3 years, HRMY stock traded as high as $62.09 and as low as $18.61.

The top ETF exchange traded funds that HRMY belongs to (by Net Assets): CALF, IJR, VTI, VB, IWM.

HRMY has underperformed the market in the last year with a price return of -16.4% while the SPY ETF gained +29.3%. HRMY has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -12.1% and -5.9%, respectively, while the SPY returned +6.4% and +3.7%, respectively.

HRMY support price is $28.30 and resistance is $29.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HRMY stock will trade within this expected range on the day.